WO2005072716A1 - 貼付剤入り包装袋 - Google Patents
貼付剤入り包装袋 Download PDFInfo
- Publication number
- WO2005072716A1 WO2005072716A1 PCT/JP2005/001272 JP2005001272W WO2005072716A1 WO 2005072716 A1 WO2005072716 A1 WO 2005072716A1 JP 2005001272 W JP2005001272 W JP 2005001272W WO 2005072716 A1 WO2005072716 A1 WO 2005072716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- packaging bag
- patch
- desiccant
- packaging
- adhesive layer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/26—Articles or materials wholly enclosed in laminated sheets or wrapper blanks
Definitions
- the present invention relates to a patch-containing packaging bag, and more particularly, to a patch-containing packaging bag having a patch accommodated therein.
- Bisoprolol (especially bisoprolol fumarate) is widely known as a drug having an action of selectively blocking a sympathetic nerve receptor, and is used for treatment of hypertension, angina pectoris, arrhythmia (tachycardia) and the like. Used.
- this bisoprolol is processed into a tablet and orally administered.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2002-308762
- transdermal administration using a patch has attracted attention as a method of administering a drug instead of oral administration.
- a patch those having a structure in which an adhesive layer containing a drug is formed on the surface of a support such as a film or a woven fabric made of a resin material are widely known.
- Such a patch is used so that the adhesive layer is in contact with the skin surface of a living body. And by the drug in the adhesive layer penetrating into the blood through the skin, The effect of the drug on the living body is exhibited.
- Transdermal administration using a patch has advantages that a drug can be continuously administered over a long period of time and that the dose can be strictly controlled. For this reason, it is expected that transdermal administration using a patch can suppress the incorporation of an excessive amount of a drug into a living body and reduce undesirable side effects of the drug.
- pisoprolol introduced into the pressure-sensitive adhesive layer of the patch was more susceptible to hydrolysis than the tablet processed as in the prior art. For this reason, it tends to be difficult to store a patch containing pisoprolol in the adhesive layer for a sufficiently practical period.
- the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a patch-containing packaging bag capable of stably storing a patch containing pisoprolol in an adhesive layer. Means for solving the problem
- the present inventors have conducted various studies to achieve long-term storage of a patch containing pisoprolol in the adhesive layer.
- a packaging bag that is, a packaging bag containing the patch.
- the present invention has been made based on these findings, and a patch comprising a packaging bag and a patch accommodated inside the packaging bag and having an adhesive layer formed on one surface of a support.
- the adhesive layer is composed of an adhesive composition containing an adhesive and bisoprolol or a pharmaceutically acceptable salt thereof, and the inside of the packaging bag has a relative humidity of 25 ° C of 25 ° C. % Or less.
- the patch is stored inside the packaging bag in which the relative humidity inside is kept at 25% or less at 25 ° C. I have.
- pisoprolol in the adhesive layer is hardly hydrolyzed under such conditions.
- the decrease over time of pisoprolol in the adhesive layer of the patch is suppressed. As a result, it becomes easy to store the patch containing pisoprolol in the adhesive layer for a long time.
- the relative humidity at 25 ° C in the packaging bag containing the patch of the present invention is maintained at 10% or less. Under these conditions, the hydrolysis reaction of bisoprole in the adhesive layer is remarkably suppressed, and the reduction of pisoprolol due to vigorous hydrolysis is hardly observed. Therefore, according to such a packaging bag with a patch, even if the patch has been stored for a long period of time, it is possible to obtain an effect that is almost the same as at the time of production.
- a desiccant is further contained in the inside of the packaging bag in the patch-containing packaging bag.
- the inside of the packaging bag is preferably maintained at the above relative humidity value by the desiccant absorbing moisture. This eliminates the need for a special operation for drying the inside of the packaging bag, and as a result, it is easy to maintain the relative humidity inside the packaging bag at the above value.
- the adhesive is introduced into the packaging bag together with the dessicant together with the drying agent.
- Moisture in the layer is absorbed by the desiccant, which makes it possible to adjust the water content of the adhesive layer to a suitable range.
- the relative humidity inside the packaging bag can be maintained at the above value, and at the same time, the packaging material that was normally required during the production of the patch It is also possible to omit the drying operation of the ingredients and the like.
- the desiccant is preferably a desiccant composed of a substance that physically adsorbs water, a so-called physical desiccant. Such a desiccant can effectively adsorb the moisture inside the packaging bag, and can easily maintain the value of the relative humidity.
- the desiccant is preferably made of a porous substance. More specifically, a desiccant which is a porous material composed of at least one material selected from the group consisting of metal oxides, zeolites and clay minerals is preferred.
- the pressure-sensitive adhesive is preferably at least one compound selected from the group consisting of a styrene-isoprene-styrene copolymer, polyisobutylene, and an acrylic polymer. These adhesives have characteristics of good adhesion to the skin and little irritation to the skin. Further, according to the pressure-sensitive adhesive layer containing these pressure-sensitive adhesive and pisoprolol, the pressure-sensitive adhesive layer easily moves pisoprolol to the skin, and as a result, the effect of the patch becomes more effective.
- the packaging bag in the patch-containing packaging bag of the present invention preferably has at least a shielding layer for shielding permeation of moisture.
- the packaging bag has a layer made of polyacrylonitrile on the innermost side of the packaging bag.
- the layer made of polyacrylonitrile has the property that migration of bisoprolol from the adhesive layer of the patch is unlikely to occur. Therefore, by providing a layer made of polyacrylonitrile as the innermost layer of the packaging bag, it is possible to suppress a decrease in storage stability due to the transfer of bisoprolol to the packaging bag.
- the hydrolysis reaction of pisoprolol in a patch containing pisoprolol in the adhesive layer can be suppressed, whereby the patch can be stably stored for a long period of time. Becomes possible.
- FIG. 1 is a cross-sectional view showing a preferred embodiment of a packaging bag with a patch of the present invention.
- FIG. 1 is a cross-sectional view showing a preferred embodiment of the packaging bag with a patch of the present invention.
- the packaging bag 1 with a patch has a packaging bag 8 composed of a pair of laminated packaging materials 7a and 7b opposed to each other, and a patch 10 accommodated in the space inside the packaging bag 8. Further, in the patch-containing packaging bag 1 shown in FIG. 1, the packaging desiccant 20 is further accommodated in the packaging bag 8. In the patch-containing packaging bag 1 having such a configuration, as described later, the relative humidity at 25 ° C. inside the packaging bag 8 is maintained at 25% or less.
- the patch 10 includes a substantially rectangular support 12 and an adhesive layer 14 laminated on substantially the entire surface of one side of the support 12. Further, a release film 16 that can be separated from the layer 14 is attached to the adhesive layer 14 of the patch 10.
- the support 12 is not particularly limited as long as it can support the adhesive layer 14, but preferably has appropriate flexibility from the viewpoint of increasing the adhesiveness of the patch 10 to the skin.
- Suitable constituent materials of the support 12 include polymers such as polyester, polypropylene, polyethylene, butyl acetate, and butyl chloride salt, and polymers obtained by copolymerizing monomers constituting these (eg, ethylene monoacetate).
- the adhesive layer 14 is composed of an adhesive and an adhesive composition containing pisoprolol as a drug or a pharmaceutically acceptable salt thereof (hereinafter, these are collectively referred to as "pisoprololi diversion compound"). It is composed.
- the adhesive in the adhesive composition a substance which has safety to the skin and has an adhesive property capable of fixing the patch on the skin surface at room temperature is preferred, and is generally known as a patch adhesive. A material made of a certain material can be applied.
- examples of the adhesive include those composed of a base, a tackifier, and a softener.
- the base material of the pressure-sensitive adhesive having this configuration includes natural rubber-based materials and synthetic rubber. System materials, acrylic resin materials, silicon resin materials, and the like. Among them, synthetic rubber-based materials and / or acryl-based resin materials are preferred because they have excellent adhesiveness and excellent drug release properties.
- examples of the synthetic rubber-based material include homopolymers such as polyisobutylene and polyisoprene, and copolymers containing these. In particular, styrene-isoprene-styrene block copolymer (hereinafter referred to as "SIS”) and polyisobutylene are preferable.
- Acrylic resin materials include (meth) acrylic acid such as acrylic acid, 1-ethylhexyl acrylate, methyl acrylate, butyl acrylate, hydroxyethyl acrylate, and 12-ethylhexyl methacrylate. Examples include a homopolymer of an acid (ester) and a copolymer containing at least one of these (meth) acrylic acids (esters). Such acrylic resin materials include, for example, 12-ethylhexyl acrylate'-butyl acetate copolymer, 12-ethylhexyl acrylate-butyl acetate-acrylic acid copolymer, and 12-ethyl acrylate.
- acrylic acid such as acrylic acid, 1-ethylhexyl acrylate, methyl acrylate, butyl acrylate, hydroxyethyl acrylate, and 12-ethylhexyl methacrylate.
- examples include a homopolymer of an acid (ester)
- Hexinoxyacetic acid biel.Hydroxyethyl acrylate copolymer 121-ethylhexyl acrylate Hexinoxyacetic acid biel.Hydroxyethyl acrylate.Acrylic acid copolymer, 12-ethylhexyl acrylate ⁇ 12-ethylhexyl methacrylate ⁇ dodecyl methacrylate copolymer.
- 2-ethylhexyl acrylate 'vinyl acetate copolymer and 2-ethylhexyl acrylate / butyl acetate / acrylic acid copolymer are preferred.
- a composite material obtained by combining a plurality of the above-described resin materials is also suitable.
- a composite material include a composite material of SIS and an acrylic resin.
- SIS is mixed with a copolymer of 12-ethylhexyl acrylate, biel acetate, and atalinoleic acid.
- Composite materials are preferred.
- tackifiers to be contained in the pressure-sensitive adhesive include an alicyclic saturated hydrocarbon resin, a rosin derivative (for example, rosin, rosin glycerin ester, hydrogenated rosin, hydrogenated rosin glycerin ester, rosin pentane) Erythritol ester), terpene resin, petroleum resin, maleic resin, and the like. Of these, alicyclic saturated hydrocarbon resins and hydrogenated rosin esters are preferred. These tackifiers may be used alone or in combination of two or more.
- softeners petroleum-based oils (for example, paraffin-based process oils, Process oils, aromatic process oils, etc.), squalane, squalene, vegetable oils (almond oil, olive oil, camellia oil, castor oil, tall oil, laccase oil), oleic acid, silicone oil, Basic acid esters (eg, dibutyl phthalate, dioctyl phthalate, etc.), liquid rubber (eg, polybutene, liquid isoprene rubber), liquid fatty acid ester (isopropyl myristate, hexyl laurate, getyl sebacate, isopropyl sebacate), diethylene glycol, polyethylene Glycol, glycolic acid salicylate, propylene glycol, dipropylene glycol, triacetin, triethyl tenoate, crotamiton and the like.
- liquid paraffin, isopir myristate pill or getyl sebacate are preferred because they
- the pisoprololui conjugate which is a drug in the pressure-sensitive adhesive composition, includes a ⁇ -receptor
- Pisoprolol fumarate having an action of selectively blocking 1 is exemplified.
- the content of the bisoprolol compound is preferably from 115 to 50% by mass, more preferably from 5 to 20% by mass.
- the content of the bisoprolol compound is less than 1% by mass, the pisoprolol conjugate is released from the adhesive layer 14, which tends to make it difficult to administer an appropriate amount of the drug at the time of use.
- it exceeds 50% by mass pisoprolol cannot be retained in the adhesive layer 14 and the adhesive properties of the adhesive layer 14 tend to be reduced.
- the content of each component is preferably within the following range. That is, it is preferable that the content of the base is 1090% by mass, the content of the tackifier is 0 to 60% by mass, and the content of the softener is 0.30% by mass of the total amount.
- the release film 16 is not particularly limited as long as it can be released from the adhesive layer 14.
- the release film 16 is preferably made of polyethylene terephthalate (hereinafter, referred to as ⁇ ) or polyester, which has been subjected to a release treatment (preferably silicon treatment). Examples thereof include those made of a resin film, paper and the like. It is preferable that the release film 16 has appropriate rigidity so that the patch 10 does not wrinkle or twist. Also, as shown in Fig. 1, peeling when using Patch 10 In order to facilitate the peeling of the film 16, it is more preferable to have an area larger than that of the adhesive layer 14. In this case, the film 16 can be easily peeled by pinching the portion where the release film 16 protrudes from the adhesive layer 14.
- the size of the patch 10 having such a configuration can be appropriately changed in consideration of a site where the patch 10 is used, a drug administration amount, and the like.
- it can be a size usually used as a patch, and one having an area of 100 cm 2 , preferably 5 to 40 cm 2 can be applied.
- the thickness of each layer can also take various values from the above viewpoint.
- the thickness of the adhesive layer 14 is 10 300 ⁇ m, preferably 25 150 ⁇ m.
- the packaging bag 8 for packaging the above-mentioned patch 10 is composed of a pair of substantially rectangular laminated packaging materials 7a and 7b arranged to face each other.
- Each of the laminated packaging materials 7a and 7b is a film-shaped laminate having a substantially rectangular shape, and is composed of a PAN layer 2 having a polyacrylonitrile (hereinafter, referred to as “PAN”) force, an A1 layer 4 composed of an anolemminium foil, and PET. It has a configuration in which the PET layer 6 and the PET layer 6 are sequentially laminated from the inside.
- the laminated packaging materials 7a and 7b opposed to each other are joined at their outer edges, whereby the periphery is closed over the entire circumference.
- the outer edges of the laminated packaging materials 7 can be joined by heat sealing or by using an adhesive.
- the PAN layer 2 hardly reacts with pisoprolol contained in the adhesive layer 14 of the patch 10 or adsorbs bisoprolol. Therefore, it plays a role in preventing drug transfer from the patch 10 to the packaging bag.
- the A1 layer 4 functions as a shielding layer that blocks the permeation of moisture and also has an excellent property of blocking the permeation of gas, light, and the like, and thus plays a role of keeping the inside of the packaging bag 8 airtight. .
- the PET layer 6 has a low oxygen permeability, it has an effect of further improving the airtightness of the packaging bag 8. According to the packaging bag 8 including these layers, the transfer of the pisoprolol compound from the patch can be suppressed, and the influence of the external atmosphere can be eliminated as much as possible, so that the patch 10 can be stored for a long time. Become.
- the relative humidity at 25 ° C. in the packaging bag 8 is maintained at 25% or less.
- the drug contained in the adhesive layer 14 of the patch 10 which is a drug contained in the pisoprololui conjugate, has the property of being extremely easily hydrolyzed with kagami. It was very difficult to apply.
- the pisoprolol compound particularly the pisoprol compound contained in the adhesive layer of the patch, has the above relative humidity (at 25 ° C). 25% or less), it was found that the hydrolysis reaction was remarkably suppressed.
- the patch-containing packaging bag 1 since the relative humidity inside the packaging bag 8 is maintained at 25% or less, the pisoprolol compound in the adhesive layer 14 of the patch 10 as described above is hydrolyzed. Is extremely unlikely to occur. Therefore, according to the patch-containing packaging bag 1 of the present embodiment, it is easy to apply pisoprolol to a patch, which was conventionally difficult. Further, the obtained patch 1 has extremely high storage stability in the form of the packaging bag 1 containing the patch.
- the relative humidity at 25 ° C in the packaging bag 8 is preferably 22% or less, preferably 20%. It is more preferably 17% or less, more preferably 15% or less, more preferably 15% or less, and most preferably 10% or less. Further, even at a temperature other than 25 ° C., for example, 40 ° C. or 60 ° C., it is more preferable that the temperature is maintained below the above value.
- the relative humidity is 0%.
- the relative humidity at 25 ° C. in the packaging bag 8 is preferably 2% or more.
- the packaging desiccant 20 is accommodated in the packaging bag 8 together with the patch 10, and the value of the relative humidity is determined by the value Achieved by Agent 20. More specifically, the packaging desiccant 20 contained in the packaging bag 8 is dried by absorbing (adsorbing) the moisture present in the packaging bag 8, thereby drying the packaging bag 8. The relative humidity in 8 is within the numerical range described above.
- the packaging desiccant 20 is composed of a desiccant packaging bag 24 and a desiccant 22 contained in the packaging bag 24.
- the desiccant packaging bag 24 can be applied without particular limitation as long as it can accommodate the desiccant 22 therein and can transmit moisture that does not prevent drying by the desiccant 22.
- a resin film made of low-density polyethylene (LDPE), a cloth material such as a woven or non-woven fabric, or a material made of a material permeable to moisture such as paper can be exemplified.
- a material that does not transmit moisture can be used in addition to the material that can transmit moisture.
- a packaging bag 24 made of the material is provided with a hole that is small enough to prevent the desiccant 22 contained therein from leaking out and that allows moisture to pass therethrough. By providing the water, its water permeability can be ensured.
- a desiccant made of a known material that is generally used as a desiccant can be used.
- the desiccant 22 is capable of physically or chemically adsorbing moisture.
- a physical desiccant capable of physically adsorbing moisture is preferable because it is easy to handle and contaminates the patch 10 and the like and has high drying ability.
- a powdery substance made of a porous substance is preferable.
- porous substance a porous substance composed of a metal oxide which is an amorphous porous substance, a porous substance composed of zeolite which is a crystalline porous substance, or a crystalline substance And a porous substance made of clay mineral which is a porous substance of an amorphous or amorphous nature. More specifically, silica gel and alumina are listed as metal oxide-based porous substances, molecular sieves are listed as zeolite-based porous substances, and montmorillonite is listed as clay mineral-based porous substances.
- silica gel, molecular sieve or montmorillonite is preferable as the substance constituting the desiccant 22. These may be used alone or in combination of two or more.
- the size of the pores is not particularly limited, and a porous material having mesopores, micropores, or the like can be appropriately selected and used.
- the packaging desiccant 20 having the above-described configuration sets the relative humidity in the packaging bag 8 to the above-described value. It is necessary to have the performance to obtain. That is, the amount of the desiccant 22 contained in the packaging desiccant 20 is such that the inside of the packaging bag 8 in the patch-containing packaging bag 1 can have the relative humidity of the value.
- the size of the packaging desiccant 20 also needs to be appropriately set based on the same viewpoint. Since the entire packaging bag 1 containing the patch is outside the compartment, it is possible within the range where the relative humidity can be achieved. It is preferably as small as possible. More specifically, the size is preferably not larger than the area of the patch 10, and is preferably as thin as possible.
- the value of the relative humidity inside the packaging bag 8 may be achieved by another method other than the method using the packaging desiccant 20 described above.
- a predetermined drying operation such as heating and putting the patch 10 under a reduced pressure condition is performed so that the amount of moisture adsorbed on the adhesive layer 14 and the like can be minimized.
- a method in which the patch 10 after the operation is immediately sealed in a packaging bag 8 capable of shielding external moisture.
- a method of packaging the patch 10 and enclosing dry nitrogen inside the packaging bag 8 may also be used. It should be noted that these methods can be implemented in combination.
- the patch-containing packaging bag 1 having such a configuration can be manufactured, for example, by the following manufacturing method.
- a base, a tackifier, a softener, and a bisoprolol compound, which are components of the adhesive layer 14, are mixed to form an adhesive composition, and then the composition is heated. To melt (soften). Next, after applying the composition in a molten (softened) state to either the surface of the support 12 or the release film 16, the applied composition layer and the other of the support 12 and the release film 16 are applied. Laminate with the one. Thus, a laminate having a structure in which the release film 16 is adhered to the patch 10 having the adhesive layer 14 formed on the support 12 is obtained.
- a solution (or mixture) obtained by dissolving the above composition in a solvent such as toluene, hexane, heptane, or ethyl acetate is applied to one of the support 12 and the release film 16,
- a solvent such as toluene, hexane, heptane, or ethyl acetate
- the moisture adsorbed in the adhesive layer 14 is also preferable to remove the moisture adsorbed in the adhesive layer 14 during the production, for example, by placing the patch 10 under heating and reduced pressure conditions.
- the patch-containing packaging bag 1 of the preferred embodiment since the patch 10 is packaged in the packaging bag 8 together with the packaging desiccant 20, the moisture in the adhesive layer 14 can be sufficiently reduced by the packaging desiccant 20. Is adsorbed. For this reason, the water content in the adhesive layer 14 can be reduced to a suitable level even after the patch 10 is packaged. Therefore, in the manufacturing method of the patch-containing packaging bag 1 having the packaging desiccant 20 in the packaging bag 8, the above-described special drying operation does not have to be performed.
- the packaging desiccant 20 is prepared, for example, by preparing a pair of substantially rectangular films for constituting the desiccant packaging bag 24 and arranging these films to face each other with the desiccant 22 interposed therebetween. It can be manufactured by joining the periphery by bonding or the like. Alternatively, the three sides of the pair of substantially rectangular films may be joined in advance, the desiccant 22 may be injected through the opening, and the other side may be closed.
- the patch 10 and the packaging desiccant 20 manufactured as described above are arranged so as to be sandwiched between the pair of laminated packaging materials 7a and 7b, the laminated packaging materials 7a and 7b are removed.
- the outer edge is joined by heat sealing, bonding or the like.
- the three sides of the pair of laminated packaging materials 7a and 7b may be joined in advance, and after the patch 10 and the packaging desiccant 20 are introduced from the opening, the other side may be closed.
- the patch-containing packaging bag 1 can be obtained.
- the relative humidity at 25 ° C. inside the packaging bag 8 is maintained at 25% or less.
- This value of the relative humidity is a value that can effectively suppress the hydrolysis of the pisoprolol compound contained in the adhesive layer 14 in the patch 10 as described above. Therefore, in the patch-containing packaging bag 1, the hydrolysis of the pisoprolol compound in the adhesive layer 14 is extremely difficult to proceed. As a result, the patch 10 can be stored for a long period of time, and even if the patch 10 has been stored for a long time, the patch 10 has a sufficiently effective effect.
- the packaging desiccant 20 is The above relative humidity value can be achieved only by coexisting with 10. For this reason, a special drying operation for removing moisture in the packaging bag 8 is not required when the patch 10 is manufactured or packed. Therefore, according to the patch-containing packaging bag 1, the patch 10 can be stored for a long time, and the manufacturing process of the patch 10 and the patch-containing packaging bag 1 can be simplified.
- the packaging bag with a patch of the present invention As described above, according to the packaging bag with a patch of the present invention, the application of the pisoprololly ligated product to the patch, which has been extremely difficult conventionally due to its high hydrolyzability, becomes easy. . And in this patch-containing packaging bag, the patch containing pisoprolol in the adhesive layer has high storage stability. For this reason, a strong patch has a very small decrease in efficacy over time during storage.
- the present invention is not necessarily limited to the above-described embodiment, and various modifications can be made.
- the patch S and the packaging bag 8 are both assumed to have a substantially rectangular force S, and the shape is not particularly limited. It may be shaped.
- the packaging bag 8 is described as being composed of the laminated packaging materials 7a and 7b having a three-layer structure.
- the number of packaging bags in the patch-containing packaging bag of the present invention is small. As long as they have the ability to block the transmission of moisture, they may have a single-layer, two-layer, or four- or more-layer structure as long as this condition is satisfied.
- Bisoprolol, liquid paraffin as a softener and getyl sebacate were placed in a container and stirred, and these were thoroughly mixed.
- This mixture was mixed with SIS as a base and an acrylic polymer (Duro-tak2194, manufactured by National 'Starch' and 'Chemical Co., Ltd.), and an alicyclic saturated hydrocarbon resin (Alcon P-100, (Arakawa Chemical) To prepare a coating solution.
- Pisoprolol fumarate as a pisoprolol compound, liquid paraffin as a softener, getyl sebacate, and anhydrous sodium acetate were placed in a mortar, and these were thoroughly mixed.
- This mixture was mixed with SIS as a base and an acrylic polymer (Duro_tak2194, manufactured by National 'Starch' and 'Chemical Co., Ltd.), and an alicyclic saturated hydrocarbon resin (Alcon P-100, Arakawa as a tackifier). (Manufactured by Kagaku Co., Ltd.) was mixed with a solution dissolved in toluene to prepare a coating solution.
- a patch was obtained in the same manner as in Production Example 1 using the obtained coating liquid.
- the blending amounts of the above components were adjusted so that the components in the adhesive layer had the contents shown in Table 2 below.
- the resultant was packaged in a desiccant packaging bag having properties to obtain a package desiccant.
- TRI-SORB registered trademark
- Sudochemie Molecular sieve (TRI-SORB (registered trademark), manufactured by Sudochemie) as a desiccant was packaged in a desiccant packaging bag having moisture permeability to obtain a package desiccant B.
- a clay mineral desiccant (DESIPAK (registered trademark), manufactured by Sudo Chemie Co., Ltd.), which is a desiccant, was packaged in a desiccant packaging bag having moisture permeability to obtain a packaging desiccant C.
- the sample containing only the desiccant in the package was stored at a constant temperature and humidity for 24 hours, and then the relative humidity in the package was measured. Then, the same condition as that of the sample in the case where the value of the relative humidity was 10% was applied as the condition “the relative humidity in the packaging bag is 10%” in this example. The relative humidity in the package was adjusted in the same manner in the following tests.
- a patch-containing packaging bag was prepared in the same procedure and under the same conditions as in Example 1, except that packaging desiccant B was used instead of packaging desiccant A.
- a packaging bag with a patch was prepared in the same procedure and under the same conditions as in Example 1 except that packaging desiccant C was used instead of packaging desiccant A.
- a packaging bag As the packaging bag, a packaging bag further provided with a moisture absorbing member layer made of low-density polyethylene containing magnesium sulfate as a filler between the PAN layer and the A1 layer of the packaging bag used in Example 1, and A patch-containing packaging bag was obtained in the same manner as in Example 1, except that the drying agent was not used.
- the moisture absorbing member layer has a property of adsorbing moisture by magnesium sulfate contained in the layer.
- a packaging bag containing a patch was prepared in the same procedure and under the same conditions as in Example 1 except that the patch obtained in Production Example 2 was used instead of the patch obtained in Production Example 1.
- a patch-containing packaging bag was prepared in the same procedure and under the same conditions as in Example 4, except that packaging desiccant B was used instead of packaging desiccant A. [0086] (Example 6)
- a patch-containing packaging bag was prepared in the same procedure and under the same conditions as in Example 4, except that packaging desiccant C was used instead of packaging desiccant A.
- a patch-containing packaging bag was prepared in the same procedure and under the same conditions as in Comparative Example 1, except that the patch obtained in Production Example 2 was used instead of the patch obtained in Production Example 1.
- a patch-containing packaging bag was obtained in the same manner as in Example 1, except that the relative humidity in the packaging bag was set to 20%.
- Each of the patch-containing packaging bags obtained in Example 17 and Comparative Example 12 was stored in a thermo-hygrostat at a temperature of 40 ° C. and a relative humidity of 75% for 3 months.
- the patch-containing packaging bags obtained in Example 1 and Comparative Example 1 were stored in a thermo-hygrostat at a temperature of 25 ° C. and a relative humidity of 60% for 12 months.
- the patch was taken out of the patch-containing packaging bag after each storage period, and the content of pisoprolol or pisoprolol fumarate (hereinafter collectively referred to as "pisoprololly conjugate") in each patch after storage was measured.
- the residual ratio (%) of the bisoprolol compound after storage in each patch was determined. Calculated.
- the content of the bisoprolol compound in each patch and the residual ratio of the pisoprololly conjugate in each packaging bag containing the patch were measured and calculated as follows. That is, first, the release film adhered to each patch after storage was peeled off, and the patch was placed in a 50 mL centrifuge tube. Into this centrifuge tube was added 10 mL of tetrahydrofuran as an extract and shaken for 1 hour. Next, an internal standard substance (isopropyl 4-aminobenzoate / methanol solution) was added to the extract, and this solution was diluted to 50 mL with methanol to obtain a test sample. Each test sample obtained was analyzed by high performance liquid chromatography.
- the content of the pisoprol compound contained in each patch was calculated based on a calibration curve obtained by analyzing a standard solution having a known concentration in advance.
- the same patch as obtained in Production Examples 1 and 2 was prepared as a patch before storage, and the pisoprolol compound contained in each patch was prepared in the same manner as described above using this. The content was calculated.
- the value (Ri) was defined as the residual ratio (%) of the pisoprolol compound after storage in each patch-containing packaging bag.
- Table 3 shows the residual ratio of the compound together with the value of the relative humidity inside the packaging bag for each patch-containing packaging bag.
- the residual ratio of the bisoprololly ligated product when stored for 12 months in a thermo-hygrostat at a temperature of 25 ° C and a relative humidity of 60% using the patch-containing packaging bags of Example 1 and Comparative Example 1.
- Table 4 shows the relative humidity values in the packaging bags for each patch containing the patch.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005517535A JP4989892B2 (ja) | 2004-01-30 | 2005-01-28 | 貼付剤入り包装袋 |
US10/587,834 US20070158227A1 (en) | 2004-01-30 | 2005-01-28 | Plaster enclosing packaging bag |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004024446 | 2004-01-30 | ||
JP2004-024446 | 2004-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005072716A1 true WO2005072716A1 (ja) | 2005-08-11 |
Family
ID=34823937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001272 WO2005072716A1 (ja) | 2004-01-30 | 2005-01-28 | 貼付剤入り包装袋 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070158227A1 (ja) |
JP (1) | JP4989892B2 (ja) |
WO (1) | WO2005072716A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10228623A (ja) * | 1997-07-28 | 1998-08-25 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
WO2007029781A1 (ja) * | 2005-09-09 | 2007-03-15 | Nitto Denko Corporation | ビソプロロール含有貼付製剤 |
WO2007069662A1 (ja) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | 貼付製剤 |
WO2007069661A1 (ja) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | ビソプロロール含有貼付製剤 |
WO2007145322A1 (ja) * | 2006-06-16 | 2007-12-21 | Toyo Aluminium Kabushiki Kaisha | 包装材及び薬剤包装用袋 |
JP2008061862A (ja) * | 2006-09-08 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 貼付剤製品 |
EP1944001A1 (en) * | 2007-01-11 | 2008-07-16 | Nitto Denko Corporation | Patch package structure |
EP1981547A2 (en) * | 2005-12-28 | 2008-10-22 | Alza Corporation | Stable therapeutic formulations |
WO2009119672A1 (ja) | 2008-03-25 | 2009-10-01 | 帝國製薬株式会社 | β遮断剤の安定化組成物およびそれを用いた経皮吸収製剤 |
JP2010285415A (ja) * | 2009-06-15 | 2010-12-24 | Hisamitsu Pharmaceut Co Inc | バレニクリン又は薬学的に許容されるバレニクリン酸付加塩を含有する経皮薬物送達システムの包装体 |
WO2011105457A1 (ja) | 2010-02-26 | 2011-09-01 | 日東電工株式会社 | 貼付製剤 |
JP2012158612A (ja) * | 2005-09-09 | 2012-08-23 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
KR20130055561A (ko) | 2010-02-26 | 2013-05-28 | 닛토덴코 가부시키가이샤 | 비소프롤롤 함유 첩부 제제 |
JP5208209B2 (ja) * | 2008-05-30 | 2013-06-12 | 日東電工株式会社 | ドネペジル含有貼付製剤およびその包装体 |
US8703178B2 (en) | 2007-03-08 | 2014-04-22 | Nitto Denko Corporation | Percutaneous administration device of bisoprolol |
WO2015034051A1 (ja) * | 2013-09-06 | 2015-03-12 | 日東電工株式会社 | ビソプロロール含有貼付製剤およびその包装体 |
JP2015110539A (ja) * | 2013-12-06 | 2015-06-18 | 久光製薬株式会社 | 4−アミノピリジン含有貼付剤 |
WO2016103999A1 (ja) * | 2014-12-26 | 2016-06-30 | ニチバン株式会社 | 貼付剤のための包装体および包装方法 |
JPWO2016121805A1 (ja) * | 2015-01-30 | 2017-08-10 | 東洋インキScホールディングス株式会社 | 貼付剤 |
WO2017170933A1 (ja) * | 2016-03-31 | 2017-10-05 | ニチバン株式会社 | 貼付剤製品 |
JP2018039852A (ja) * | 2017-12-18 | 2018-03-15 | 日東電工株式会社 | ビソプロロール含有貼付製剤およびその包装体 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2090310B1 (en) * | 2006-12-01 | 2013-07-10 | Nitto Denko Corporation | Method for prevention of coloration in donepezil-containing skin adhesive preparation, and method for reducing the production of donepezil analogue in donepezil-containing skin adhesive preparation |
WO2008066179A1 (fr) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Préparation d'absorption percutanée |
KR101539771B1 (ko) * | 2007-12-14 | 2015-07-27 | 닛토덴코 가부시키가이샤 | 패치 포장 구조체 |
CA2646621C (en) * | 2007-12-14 | 2016-06-28 | Nitto Denko Corporation | Patch package structure |
CA2725484A1 (en) * | 2008-05-30 | 2009-12-03 | Eisai R&D Management Co., Ltd. | Percutaneously absorbable preparation |
EP2376348A4 (en) * | 2008-12-10 | 2012-09-05 | Merck Sharp & Dohme | PACKAGING FOR OXYGEN-SENSITIVE PHARMACEUTICAL PRODUCTS |
US20110303570A1 (en) * | 2009-03-02 | 2011-12-15 | Astellas Pharma Inc. | Package of solid pharmaceutical preparation |
US20120090275A1 (en) * | 2009-04-24 | 2012-04-19 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch-containing package bag and method for storing adhesive patch |
DE102009032744A1 (de) * | 2009-07-11 | 2011-01-13 | Thinxxs Microtechnology Ag | Fluidspeicher |
US20120006697A1 (en) * | 2010-07-07 | 2012-01-12 | Airsec S.A.S. | Container having improved oxygen barrier function |
US9096368B2 (en) * | 2011-01-19 | 2015-08-04 | Boston Scientific Scimed, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
US8973748B2 (en) * | 2011-01-19 | 2015-03-10 | Boston Scientific Scime, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
CN104718138B (zh) | 2013-01-25 | 2017-07-21 | 凸版印刷株式会社 | 柔性包装体 |
US20150108015A1 (en) * | 2013-10-17 | 2015-04-23 | Pouch Pac Innovations, Llc | Pouch with absorbent liner and method of forming |
ES2899250T3 (es) * | 2015-06-17 | 2022-03-10 | Toa Eiyo Ltd | Preparación adhesiva que contiene bisoprolol |
JP6065965B2 (ja) * | 2015-11-30 | 2017-01-25 | 大日本印刷株式会社 | 貼付薬用包装袋 |
US20180319131A1 (en) * | 2017-05-03 | 2018-11-08 | Switch Materials Inc. | Packaged film assembly for lamination between substrates |
CN112078947B (zh) * | 2019-06-13 | 2022-06-10 | 江苏佳成特种玻璃制造有限公司 | 一种汽车夹层玻璃包装袋 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04202131A (ja) * | 1990-11-29 | 1992-07-22 | Tanabe Seiyaku Co Ltd | 長期間安定な経口用医薬製剤 |
JPH0656653A (ja) * | 1992-04-03 | 1994-03-01 | Sansei Seiyaku Kk | 貼付剤用剥離紙 |
JPH08325141A (ja) * | 1995-05-31 | 1996-12-10 | Minnesota Mining & Mfg Co <3M> | 乾燥剤を含有する経皮薬物供給具 |
JPH10505342A (ja) * | 1994-08-27 | 1998-05-26 | エルティーエス ローマン テラピイー システム ゲーエムベーハー | 加水分解に対する保護を備えた経皮性治療システム |
JPH11343233A (ja) * | 1998-05-28 | 1999-12-14 | Sekisui Chem Co Ltd | 外用貼付剤 |
JP2002308762A (ja) * | 2001-04-11 | 2002-10-23 | Nichiko Pharmaceutical Co Ltd | ビソプロロール含有製剤 |
JP2003313122A (ja) * | 2002-04-19 | 2003-11-06 | Nitto Denko Corp | ビソプロロール含有貼付剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310559A (en) * | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
JPH0343156Y2 (ja) * | 1984-10-17 | 1991-09-10 | ||
US4732808A (en) * | 1985-11-14 | 1988-03-22 | Minnesota Mining And Manufacturing Company | Macromer reinforced pressure sensitive skin adhesive sheet material |
US4861632A (en) * | 1988-04-19 | 1989-08-29 | Caggiano Michael A | Laminated bag |
JPH0572675A (ja) * | 1991-04-15 | 1993-03-26 | Canon Inc | カメラ |
US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
JP3908795B2 (ja) * | 1994-11-29 | 2007-04-25 | 久光製薬株式会社 | ケトチフェン含有経皮投与製剤 |
DE19600347A1 (de) * | 1996-01-08 | 1997-07-10 | Lohmann Therapie Syst Lts | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
US6689197B2 (en) * | 1996-09-19 | 2004-02-10 | Sud-Chemie Inc. | Desiccant composition |
DE19649534B4 (de) * | 1996-11-29 | 2004-05-06 | Lts Lohmann Therapie-Systeme Ag | Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern |
US5938012A (en) * | 1997-03-19 | 1999-08-17 | Innoflex, Incorporated | Storage bag with moisture emitting pad |
US6660295B2 (en) * | 1997-09-30 | 2003-12-09 | Alza Corporation | Transdermal drug delivery device package with improved drug stability |
JP2001009985A (ja) * | 1999-07-02 | 2001-01-16 | Hisamitsu Pharmaceut Co Inc | 貼付剤用包装袋及び包装貼付剤 |
US6176371B1 (en) * | 1999-08-13 | 2001-01-23 | Biosafe Laboratories, Inc. | Biological sample storage package and method for making same |
US6905016B2 (en) * | 2000-03-14 | 2005-06-14 | Noven Pharmaceuticals, Inc. | Packaging system for transdermal drug delivery systems |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
NZ529146A (en) * | 2001-04-23 | 2004-10-29 | Noven Pharma | Packaging system for transdermal drug delivery systems |
-
2005
- 2005-01-28 JP JP2005517535A patent/JP4989892B2/ja not_active Expired - Lifetime
- 2005-01-28 US US10/587,834 patent/US20070158227A1/en not_active Abandoned
- 2005-01-28 WO PCT/JP2005/001272 patent/WO2005072716A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04202131A (ja) * | 1990-11-29 | 1992-07-22 | Tanabe Seiyaku Co Ltd | 長期間安定な経口用医薬製剤 |
JPH0656653A (ja) * | 1992-04-03 | 1994-03-01 | Sansei Seiyaku Kk | 貼付剤用剥離紙 |
JPH10505342A (ja) * | 1994-08-27 | 1998-05-26 | エルティーエス ローマン テラピイー システム ゲーエムベーハー | 加水分解に対する保護を備えた経皮性治療システム |
JPH08325141A (ja) * | 1995-05-31 | 1996-12-10 | Minnesota Mining & Mfg Co <3M> | 乾燥剤を含有する経皮薬物供給具 |
JPH11343233A (ja) * | 1998-05-28 | 1999-12-14 | Sekisui Chem Co Ltd | 外用貼付剤 |
JP2002308762A (ja) * | 2001-04-11 | 2002-10-23 | Nichiko Pharmaceutical Co Ltd | ビソプロロール含有製剤 |
JP2003313122A (ja) * | 2002-04-19 | 2003-11-06 | Nitto Denko Corp | ビソプロロール含有貼付剤 |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10228623A (ja) * | 1997-07-28 | 1998-08-25 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
WO2007029781A1 (ja) * | 2005-09-09 | 2007-03-15 | Nitto Denko Corporation | ビソプロロール含有貼付製剤 |
JP2007099759A (ja) * | 2005-09-09 | 2007-04-19 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
JP2012158612A (ja) * | 2005-09-09 | 2012-08-23 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
AU2006288260B2 (en) * | 2005-09-09 | 2011-05-26 | Nitto Denko Corporation | Adhesive preparation containing bisoprolol |
KR101374436B1 (ko) * | 2005-12-13 | 2014-03-17 | 도아 에이요 가부시키가이샤 | 비소프롤롤 함유 접착 제제 |
WO2007069662A1 (ja) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | 貼付製剤 |
WO2007069661A1 (ja) * | 2005-12-13 | 2007-06-21 | Nitto Denko Corporation | ビソプロロール含有貼付製剤 |
JP2007186499A (ja) * | 2005-12-13 | 2007-07-26 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
CN101330910B (zh) * | 2005-12-13 | 2012-07-18 | 日东电工株式会社 | 含比索洛尔的粘贴制剂 |
US8298572B2 (en) | 2005-12-13 | 2012-10-30 | Nitto Denko Corporation | Adhesive pharmaceutical preparation containing bisoprolol |
EP1981547A2 (en) * | 2005-12-28 | 2008-10-22 | Alza Corporation | Stable therapeutic formulations |
EP1981547A4 (en) * | 2005-12-28 | 2009-05-06 | Alza Corp | STABLE THERAPEUTIC FORMULATIONS |
WO2007145322A1 (ja) * | 2006-06-16 | 2007-12-21 | Toyo Aluminium Kabushiki Kaisha | 包装材及び薬剤包装用袋 |
JP2008061862A (ja) * | 2006-09-08 | 2008-03-21 | Hisamitsu Pharmaceut Co Inc | 貼付剤製品 |
EP1944001A1 (en) * | 2007-01-11 | 2008-07-16 | Nitto Denko Corporation | Patch package structure |
US9433533B2 (en) | 2007-01-11 | 2016-09-06 | Nitto Denko Corporation | Patch package structure |
US8703178B2 (en) | 2007-03-08 | 2014-04-22 | Nitto Denko Corporation | Percutaneous administration device of bisoprolol |
WO2009119672A1 (ja) | 2008-03-25 | 2009-10-01 | 帝國製薬株式会社 | β遮断剤の安定化組成物およびそれを用いた経皮吸収製剤 |
JP5208209B2 (ja) * | 2008-05-30 | 2013-06-12 | 日東電工株式会社 | ドネペジル含有貼付製剤およびその包装体 |
JP2010285415A (ja) * | 2009-06-15 | 2010-12-24 | Hisamitsu Pharmaceut Co Inc | バレニクリン又は薬学的に許容されるバレニクリン酸付加塩を含有する経皮薬物送達システムの包装体 |
US9326952B2 (en) | 2010-02-26 | 2016-05-03 | Nitto Denko Corporation | Adhesive skin patch |
KR20130055560A (ko) | 2010-02-26 | 2013-05-28 | 닛토덴코 가부시키가이샤 | 첩부 제제 |
KR20130055561A (ko) | 2010-02-26 | 2013-05-28 | 닛토덴코 가부시키가이샤 | 비소프롤롤 함유 첩부 제제 |
WO2011105457A1 (ja) | 2010-02-26 | 2011-09-01 | 日東電工株式会社 | 貼付製剤 |
JP2015051947A (ja) * | 2013-09-06 | 2015-03-19 | 日東電工株式会社 | ビソプロロール含有貼付製剤およびその包装体 |
CN105517543A (zh) * | 2013-09-06 | 2016-04-20 | 日东电工株式会社 | 含有比索洛尔的贴剂及其包装体 |
WO2015034051A1 (ja) * | 2013-09-06 | 2015-03-12 | 日東電工株式会社 | ビソプロロール含有貼付製剤およびその包装体 |
JP2015110539A (ja) * | 2013-12-06 | 2015-06-18 | 久光製薬株式会社 | 4−アミノピリジン含有貼付剤 |
WO2016103999A1 (ja) * | 2014-12-26 | 2016-06-30 | ニチバン株式会社 | 貼付剤のための包装体および包装方法 |
JPWO2016103999A1 (ja) * | 2014-12-26 | 2017-10-05 | ニチバン株式会社 | 貼付剤のための包装体および包装方法 |
JPWO2016121805A1 (ja) * | 2015-01-30 | 2017-08-10 | 東洋インキScホールディングス株式会社 | 貼付剤 |
WO2017170933A1 (ja) * | 2016-03-31 | 2017-10-05 | ニチバン株式会社 | 貼付剤製品 |
JP2018039852A (ja) * | 2017-12-18 | 2018-03-15 | 日東電工株式会社 | ビソプロロール含有貼付製剤およびその包装体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005072716A1 (ja) | 2007-09-13 |
US20070158227A1 (en) | 2007-07-12 |
JP4989892B2 (ja) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4989892B2 (ja) | 貼付剤入り包装袋 | |
JP6054013B2 (ja) | 貼付製剤 | |
US6991095B1 (en) | Packaging bag for plaster and packaged plaster | |
JP5329197B2 (ja) | 貼付剤包装構造 | |
JP5933974B2 (ja) | 貼付剤入り包装袋、及び貼付剤の保存方法 | |
US9155710B2 (en) | Ropinirole-containing patch and package thereof | |
JP4139689B2 (ja) | 経皮薬物送達システムのための包装システム | |
JP5329198B2 (ja) | 貼付剤包装構造 | |
RU2440811C2 (ru) | Устройство для трансдермального введения бисопролола | |
WO2005072675A1 (ja) | 貼付剤入り包装袋及び薬物移行抑制方法 | |
WO2015174502A1 (ja) | リバスチグミンを含有する貼付剤のための包装体 | |
CN116887796A (zh) | 含有双氯芬酸的贴附剂包装制品及双氯芬酸钠的稳定化方法 | |
JPH05305108A (ja) | 貼付剤の包装構造 | |
JP2013216343A (ja) | 貼付剤の包装構造および貼付剤の包装方法 | |
JPH09299445A (ja) | 薬物含有貼付剤用包装体 | |
TWI636800B (zh) | 含有可樂寧之貼劑 | |
WO2017170933A1 (ja) | 貼付剤製品 | |
JP2010285415A (ja) | バレニクリン又は薬学的に許容されるバレニクリン酸付加塩を含有する経皮薬物送達システムの包装体 | |
CN105517543A (zh) | 含有比索洛尔的贴剂及其包装体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517535 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007158227 Country of ref document: US Ref document number: 10587834 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10587834 Country of ref document: US |